CD274 and neoplasm: Over 50 different tumor types have approval for the use of T-cell targeted immunomodulators blocking immune checkpoints like cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), programmed death-1 (PD-1), or programmed death ligand 1 (PD-L1).1 However, because of their unique mechanism of action, ICIs present their own set of adverse events (AEs), called immune-related adverse events.